1. Academic Validation
  2. HAND2 assists MYCN enhancer invasion to regulate a noradrenergic neuroblastoma phenotype

HAND2 assists MYCN enhancer invasion to regulate a noradrenergic neuroblastoma phenotype

  • Cancer Res. 2023 Jan 4;CAN-22-2042. doi: 10.1158/0008-5472.CAN-22-2042.
Man Xu 1 Ming Sun 1 Xiyuan Zhang 1 Rosa Nguyen 2 Haiyan Lei 1 Jack F Shern 1 Carol J Thiele 1 Zhihui Liu 1
Affiliations

Affiliations

  • 1 National Cancer Institute, Bethesda, MD, United States.
  • 2 National Cancer Institute, Bethesda, United States.
Abstract

Noradrenergic neuroblastoma (NB) is characterized by a core transcriptional regulatory circuitry (CRC) comprised of transcription factors (TFs) such as PHOX2B, HAND2 and GATA3, which form a network with MYCN. At normal physiologic levels, MYCN mainly binds to promoters but when aberrantly upregulated as in NB, MYCN also binds to enhancers. Here, we investigated how MYCN invades enhancers and whether CRC TFs play a role in this process. HAND2 was found to regulate chromatin accessibility and assist MYCN binding to enhancers. Moreover, HAND2 cooperated with MYCN to compete with nucleosomes to regulate global gene transcription. The cooperative interaction between MYCN and HAND2 could be targeted with an Aurora A kinase inhibitor plus a histone deacetylase inhibitor, resulting in potent downregulation of both MYCN and the CRC TFs and suppression of MYCN-amplified NB tumor growth. This study identifies cooperation between MYCN and HAND2 in NB and demonstrates that simultaneously targeting MYCN and CRC TFs is an effective way to treat this aggressive pediatric tumor.

Figures
Products